Novartis is being sued in Japan for drug advertising exaggeration

Source: Yomiuri Shimbun December 19, 2013 according to the website of Yomiuri Shimbun, Japan December 18 According to the daily, because the head of Novartis has tampered with the clinical research data of the high blood pressure treatment drug "pronoun" without permission, the Ministry of health, labor and welfare believes that the act of falsifying the drug data and advertising (exaggerating in the advertising) is suspected of violating the drug law, and plans to prosecute the general agent of Novartis and the relevant personnel responsible for advertising with the company As for the investigation of the Ministry of health, labor and welfare, the general agent of Novartis denied any connection with the advertising incident, and hoped that the Ministry of health, labor and welfare would know the actual situation of the company search According to the Japanese drug law, it is expressly forbidden to exaggerate the functions of pharmaceuticals in advertisements Those who violate the regulation will be sentenced to fixed-term imprisonment of less than two years or a fine of less than 2 million yen According to incomplete statistics, there are no cases of administrative punishment or criminal punishment due to exaggeration in advertisements after 1975 The Ministry of health, labor and welfare, as the prosecution, will make a final investigation centered on the Tokyo local police station.